Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 30, 2020

BioNTech and Pfizer dose participants in Covid-19 vaccine trial

BioNTech and Pfizer have dosed participants in the first cohort of a Phase I/II clinical trial of Covid-19 vaccine candidate BNT162 in Germany.

BioNTech and Pfizer have dosed participants in the first cohort of a Phase I/II clinical trial of Covid-19 vaccine candidate BNT162 in Germany.

Dosing in the trial was commenced on 23 April and 12 participants have received the vaccine so far.

The companies also intend to trial BNT162 in the US following regulatory approval.

BioNTech said in a statement: “The trial is the first clinical trial of a Covid-19 vaccine candidate in Germany. Pfizer and BioNTech plan to initiate trials for BNT162 in the US upon regulatory approval, which is expected shortly.”

Earlier this month, BioNTech and Pfizer secured approval from the German regulatory authority,  Paul-Ehrlich-Institut, for the Phase I/II clinical trial of BioNTech’s BNT162.

The trial’s dose escalation part will enrol around 200 healthy participants aged 18 to 55. Participants will be administered with a dose range of 1µg to 100µg.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

BioNTech and Pfizer aim to potentially establish the optimal dose for further studies. The study will also assess the vaccine candidate’s safety and immunogenicity.

The trial will also study the impact of repeated vaccination after a prime injection for three of BioNTech’s Covid-19-focused vaccine candidates, which are made of uridine containing mRNA (uRNA) or nucleoside modified mRNA (modRNA).

A fourth vaccine candidate containing self-amplifying mRNA (saRNA) will be assessed after a single dose.

The second part of the Phase I/II trial will enrol patients at a higher risk of severe Covid-19 infection.

BNT162 is being jointly developed by BioNTech and Pfizer.

BioNTech will be responsible for the clinical supply of the vaccine from its mRNA manufacturing facilities in Europe during the clinical development stage.

The company is also working with Fosun Pharma to develop BNT162 in China, with plans to conduct clinical trials in the country.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy